Abbott Laboratories (NYSE: $ABT) announced Q1 fiscal 2025 results on Wednesday, April 16th. The healthcare firm posted $1.33 billion in net income. Adjusted earnings reached […]
Category: Healthcare
Johnson & Johnson (NYSE: JNJ) Releases Q1 Fiscal 2025 Results: Is This Dividend Stock Still a Buy Amid Tariff Fears?
Johnson & Johnson (NYSE: $JNJ), a major multinational that produces medical devices and pharmaceuticals, released its first-quarter fiscal 2025 results on Tuesday, April 15, 2025, […]
OKYO Pharma (NASDAQ: OKYO) Reports Positive Stability Data For Urcosimod: Is Now The Time To Buy OKYO?
OKYO Pharma (NASDAQ: $OKYO), a clinical stage biopharmaceutical company, announced a major stability milestone for its drug candidate urcosimod on Monday, March 31, 2025. Details […]
Alvotech (NASDAQ: ALVO) Releases Q4 Fiscal 2024 Results: Is This Biotech A Buy in 2025?
Alvotech (NASDAQ: $ALVO), a leading global biopharmaceutical manufacturer of biosimilars, released its Q4 fiscal 2024 results on Wednesday, March 26, 2024, after markets closed. Here […]
Hoth Therapeutics (NASDAQ: HOTH) Unveils Plan To Submit HT-001 Expanded Access Application Amid Double Digit Growth in The Past Week: What To Know About Hoth
Hoth Therapeutics (NASDAQ: $HOTH), a clinical-stage biopharmaceutical working to develop innovative therapies, announced on Monday, March 10, 2025, that it planned to submit an Expanded […]
TG Therapeutics (NASDAQ: TGTX) Releases Q4 Fiscal 2024 Results Following Release Of Promising Data On New MS Drug: Is Now The Time To Invest In TGTX?
TG Therapeutics (NASDAQ: $TGTX), a commercial-stage biopharmaceutical company, released its Q4 fiscal 2024 results on Monday, March 3, 2025, before markets opened. Here is a […]